On this page
What it is
Kisspeptins are peptide fragments made from the KISS1 precursor. They bind the KISS1 receptor, also called GPR54, and sit upstream of the reproductive hormone axis that controls puberty, ovulation, and fertility.
Kisspeptin-10 is the shortest active fragment and the form commonly sold as a research vial. Much of the best human IVF evidence used kisspeptin-54, the major circulating human form. Results from one form cannot be treated as interchangeable with an unregulated vial of another.
What people research it for
Triggered egg maturation in IVF research
Early human dataIn a 53-woman study, kisspeptin-54 produced mature eggs at every tested level. Embryo transfer occurred in 49 participants, with clinical pregnancy reported in 12.
Worked in women at high OHSS risk
Early human dataA 60-woman phase 2 study reported oocyte maturation in 95% and no moderate, severe, or critical ovarian hyperstimulation syndrome after kisspeptin-54.
Increased LH pulsatility
Early human dataIn five women with hypothalamic amenorrhea, kisspeptin-54 infusion temporarily tripled the peak number of LH pulses compared with vehicle.
Reactivated hormones in a tiny exploratory study
Early human dataKisspeptin-10 increased LH, FSH, sex steroids, and ovarian activity in two women with hyperprolactinemic amenorrhea. Two participants cannot establish a treatment effect.
How it works
Kisspeptin activates KISS1 receptors on gonadotropin-releasing hormone neurons in the hypothalamus. GnRH then signals the pituitary to release luteinizing hormone and follicle-stimulating hormone, which act on the ovaries or testes.
The response depends on sex, reproductive stage, baseline hormone status, peptide form, and exposure pattern. Brief stimulation can increase LH release, while repeated high exposure can cause desensitization. That makes simple claims about boosting fertility or testosterone misleading.
What the research actually shows
A first IVF study enrolled 53 women and tested a single kisspeptin-54 injection before egg retrieval. Egg maturation occurred at every tested level. Forty-nine women reached fertilization and embryo transfer, with biochemical pregnancy in 21 and clinical pregnancy in 12.
A phase 2 study then enrolled 60 women at high risk for ovarian hyperstimulation syndrome. Oocyte maturation occurred in 95%. Among 51 transfers, live birth was reported in 45%, and no participant developed moderate, severe, or critical OHSS. The open-label design and specialized IVF setting limit broader conclusions.
A randomized phase 2 study of 62 high-risk IVF patients compared a second kisspeptin-54 injection with saline after all had received an initial injection. An oocyte yield of at least 60% occurred in 71% with the second injection versus 45% with saline. The authors called for direct comparisons with established egg-maturation triggers.
In five women with hypothalamic amenorrhea, intravenous kisspeptin-54 temporarily increased LH pulsatility. The peak mean pulse count rose from 1.6 during vehicle infusion to 5.0 during kisspeptin exposure, but responses varied between participants and the study was extremely small.
An exploratory report studied kisspeptin-10 in only two women with cabergoline-resistant hyperprolactinemic amenorrhea. LH, FSH, estradiol, testosterone, and inhibin B increased during infusion. This supports pathway biology but cannot establish clinical effectiveness or safety.
Human studies focus on supervised reproductive endocrinology, not anti-aging, general wellness, bodybuilding, or unsupervised fertility enhancement. Kisspeptin is not FDA approved, and long-term safety, comparative effectiveness, and effects of retail kisspeptin-10 products remain uncertain.
Handling & storage
Storage at a glance
Vendor consensus- Lyophilized
- below -18°C
- about 3 weeks at room temperature according to technical listings
- Keep sealed and desiccated.
- Reconstituted
- 4°C
- Use within 2 to 7 days
- Technical supplier guidance for kisspeptin-10, not a clinical product label.
- Light
- Protect from moisture and unnecessary light exposure.
- Room temperature
- Sealed dry kisspeptin-10 is listed as stable for about 3 weeks.
- Reconstitution
- product-specified sterile diluent
- Use single-use frozen aliquots for longer laboratory storage and avoid repeated freeze-thaw cycles.
Basis: Vendor consensus. Sources: ProSpec kisspeptin-10 technical page, BioHippo kisspeptin-10 technical listing
Two checked technical listings for kisspeptin-10 describe a lyophilized powder kept desiccated below -18°C. They list about three weeks of room-temperature stability for the sealed dry material, which is a supplier handling allowance rather than a universal expiry.
The same listings specify 4°C for 2 to 7 days after reconstitution, with frozen single-use aliquots for longer laboratory storage and minimal freeze-thaw exposure. The pages appear to describe the same manufacturer catalog item, so the agreement does not justify high confidence.
Safety & cautions
Kisspeptin can alter LH, FSH, estrogen, progesterone, and testosterone signaling. Potential risks include headache, flushing, abdominal symptoms, ovarian over-response, menstrual disruption, and unintended effects on fertility or pregnancy. Repeated exposure may produce desensitization rather than a predictable hormone increase.
It is not an approved fertility or hormone treatment. Safety is not established for pregnancy outside a supervised fertility study, hormone-sensitive cancers, pituitary disease, ovarian disorders, adolescents, or long-term use. Research vials add separate risks involving identity, strength, sterility, and endotoxin contamination.
Watch Kisspeptin prices
We'll email you when prices drop, a discount code changes, or new lab results come in for Kisspeptin. No spam — only real changes.
Frequently asked questions
Is kisspeptin FDA approved?
No. There is no FDA-approved kisspeptin drug.
What does kisspeptin do?
It activates a hypothalamic pathway upstream of GnRH, which can increase LH and FSH release from the pituitary.
Is kisspeptin-10 the same as kisspeptin-54?
No. Both activate the same receptor, but they differ in length, circulation, and studied exposure. Most IVF trials used kisspeptin-54.
Can kisspeptin improve fertility?
Small supervised IVF studies show that kisspeptin-54 can trigger egg maturation. That does not establish an unsupervised fertility treatment or prove that retail kisspeptin-10 has the same effect.
Does kisspeptin raise testosterone?
It can stimulate the reproductive hormone axis, but responses depend on baseline biology and exposure. It is not an approved testosterone treatment.
Can kisspeptin stop working with repeated exposure?
Yes. Human research has reported desensitization with repeated high exposure, which is one reason the response is not simply more peptide equals more effect.
How should laboratory kisspeptin-10 be stored?
Checked technical listings specify dry storage below -18°C and 4°C for 2 to 7 days after reconstitution. Product-specific instructions take priority.
Sources
- Kisspeptin-54 egg maturation study in IVF
- Phase 2 kisspeptin-54 study in women at high OHSS risk
- Randomized second-injection kisspeptin-54 IVF study
- Kisspeptin-54 and LH pulsatility in hypothalamic amenorrhea
- Kisspeptin-10 in hyperprolactinemic amenorrhea
- ProSpec kisspeptin-10 technical page
- BioHippo kisspeptin-10 technical listing
Last reviewed September 17, 2026. This guide is educational and research-focused, not medical advice. Kisspeptin products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.
GO DEEPER
This guide covers one compound. We wrote the book on all 45.
The Peptide Handbook takes everything we know from testing vendors for a living and turns it into five readable books: what each compound actually does, what the evidence really says, and the honest call when the answer is "skip this one." Plus the dosing tables, calendars, and trackers that make it usable.
From the community
Ask a question →No Kisspeptin discussions yet — ask the first question and our team will answer.